Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Disclosure statements are available on the authors' profiles:
Obesity and Effects of Dapagliflozin on Cardiovascular and Renal Outcomes in Patients With Type 2 Diabetes Mellitus in the DECLARE-TIMI 58 TrialEur Heart J 2021 Aug 24;[EPub Ahead of Print], K Oyama, I Raz, A Cahn, J Kuder, SA Murphy, DL Bhatt, LA Leiter, DK McGuire, JPH Wilding, KS Park, A Goudev, R Diaz, J Špinar, IAM Gause-Nilsson, O Mosenzon, MS Sabatine, SD Wiviott
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.